Neurological focus Target CNS diseases with RNA interference platform to engage potential collaborators and customers in neuroscience, gene therapy, and rare neurological disorder spaces. Highlight durable, selective brain and spinal cord gene silencing as a differentiator for CNS programs.

Strategic collaboration Leverage the Genentech partnership to position Atalanta as a co-development or out-licensing partner for large pharma seeking CNS RNAi capabilities, and explore additional collaborations to expand the pipeline and funding opportunities.

Recent leadership Recent CEO appointment signals strategic pivot and growth readiness; align outreach to a leadership-driven buyer persona in biotech and pharma BD teams, emphasizing vision, execution capability, and milestones achieved under new leadership.

Strong funding runway Series B success and multi-year funding alongside existing revenue suggest financial credibility for partnering negotiations, milestone-driven deals, and potential co-funding arrangements to de-risk joint CNS programs.

Clinical pipeline momentum Two RNAi CNS programs advancing toward clinical trials present near-term collaboration and licensing opportunities; target conversations around platform-enabled target silencing, delivery to brain and spinal cord, and potential go/no-go milestones to structure deals.